Ann Van de Velde

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination

Viggo Van Tendeloo, Ann Van de Velde, Ann Van Driessche et al. · Proceedings of the National Academy of Sciences · 2010 · 370 citations · Full text

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients

Ellen Van Gulck, Erika Vlieghe, Marc Vekemans et al. · AIDS · 2011 · 108 citations

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Charles Dumontet, Cyrille Hulin, Meletios Α. Dimopoulos et al. · Leukemia · 2018 · 70 citations · Full text

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

Michel Delforge, Dominik Selleslag, Yves Béguin et al. · Leukemia Research · 2014 · 66 citations

Hematological Malignancy, Oncology, Least Six +7